Biosimilar Contract Manufacturing Companies

Boehringer Ingelheim expands its biosimilars manufacturing capacity with a new 800 million euro site in Vienna, Austria: This strategic move reinforces their commitment to the biosimilar market and strengthens their European presence.

Samsung Biologics partners with GSK for the manufacturing of GSK's monoclonal antibody and products, including lupus treatments like Benlysta: This collaboration highlights the growing trend of major pharmaceutical companies outsourcing biosimilar manufacturing for improved efficiency and cost-effectiveness.

Lonza signs a multi-year agreement with Amgen for the development and manufacturing of a biosimilar: This deal showcases the increasing demand for reliable and experienced contract manufacturing partners with expertise in biosimilars.

WuXi AppTec launches a new "Center of Excellence" dedicated to biosimilar development and manufacturing in Ireland: This expansion underscores WuXi AppTec's focus on providing comprehensive biosimilar solutions for global clients.

Samsung Biologics opens its third manufacturing facility in South Korea, dedicated to biosimilars and cell therapy products: This investment signals the company's commitment to becoming a leading player in the biosimilar contract manufacturing market.

Fujifilm Diosynth Biotechnologies expands its biomanufacturing capacity in North Carolina, USA: This expansion caters to the rising demand for biosimilar manufacturing in the region and strengthens Fujifilm's position in the North American market.

• Boehringer Ingelheim GmbH


• Lonza, Catalent Inc.


• Biocon


• IQVIA Inc.


• AGC Biologics.


• Samsung Biologics.


• WuXi Biologics.


• Element Materials Technology


• Rentschler Biopharma SE


• Avid Bioservice, Inc.


• Alcami Corporation, Inc.


• Fujifilm Kyowa Kirin Biologics Co., Ltd.


• Thermo Fisher Scientific Inc.


• Almac Group